New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: Cytotoxic and antitumor activities

Journal of Medicinal Chemistry

Volumn 51, Issue 12, 2008, Pages 3414-3421

  Keller, Laurent ^a   Beaumont, Stéphane ^a   Liu, Jian Miao ^a   Thoret, Sylviane ^a   Bignon, Jérôme S ^a   Wdzieczak Bakala, Joanna ^a   Dauban, Philippe ^a   Dodd, Robert H ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 IODOINDOLE 2 CARBOXYLATE DERIVATIVE; 5 ETHYL 5,8 DIHYDROINDOLO[2,3 D][2]BENZAZEPIN 7(6H) ONE; ALKYL GROUP; BENZAZEPINE DERIVATIVE; BORONIC ACID DERIVATIVE; INDOLE DERIVATIVE; LACTAM DERIVATIVE; TUBULIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIZATION; CYTOTOXICITY; DRUG STRUCTURE; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; INHIBITION KINETICS; MICROTUBULE ASSEMBLY; SUZUKI REACTION;

ANIMALS; APOPTOSIS; BENZAZEPINES; BIOPOLYMERS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; NEOPLASM TRANSPLANTATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUBULIN; TUBULIN MODULATORS;

EID: 45749137266     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701466p     Document Type: Article

References (39)

1. Downing, K. H.; Nogales, E. Tubulin and microtubule structure. Curr. Opin. Cell Biol. 1998, 10, 16-22.
2. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2002, 1, 1-17.
3. Correia, J. J.; Lobert, S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr. Pharm. Des. 2001, 7, 1213-1228.
4. Jordan, M. A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 1998, 18, 259-296.
5. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253-265.
6. (a) Guéritte, F.; Fahy, J. The Vinca Alkaloids. In Anticancer Agents from Natural Products; Cragg, G. M., Kingston, D. G. I., Newman, D. J. Eds.; CRC Press: Boca Raton, FL, 2005; pp 123-135.
7. (b) Kingston, D. G. I. Taxol and Its Analogs. In Anticancer Agents from Natural Products; Cragg, G. M., Kingston, D. G. I., Newman, D. J. Eds.; CRC Press: Boca Raton, FL, 2005; pp 89-122.
8. (c) Höfle, G.; Reichenbach, H. Epothilone, a Myxobacterial Metabolite with Promising Antitumor Activity. In Anticancer Agents from Natural Products; Cragg, G. M., Kingston, D. G. I., Newman, D. J. Eds.; CRC Press: Boca Raton, FL, 2005; pp 413-450.
9. (d) Gunasekera, S. P.; Wright, A. E. Chemistry and Biology of the Discodermolides, Potent Mitotic Spindle Poisons. In Anticancer Agents from Natural Products; Cragg, G. M., Kingston, D. G. I., Newman, D. J. Eds.; CRC Press: Boca Raton, FL, 2005; pp 171-189.
10. Amoroso, E. C. Colchicine and tumour growth. Nature (London) 1935, 135, 266-267.
11. Capraro, H.-G.; Brossi, A. In The Alkaloids, Vol. 23, Brossi, A. Ed.; Academic Press: New York, 1984, pp 1-70.
12. Bai, R.; Covell, D. G.; Pei, X. F.; Ewell, J. B.; Nguyen, N. Y.; Brossi, A.; Hamel, E. Mapping the binding site of colchicinoids on beta-tubulin: 2-chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354. J. Biol. Chem. 2000, 275, 40433-40452.
13. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428, 198-202.
14. (a) Nakagawa-Goto, K.; Chen, C. X.; Hamel, E.; Wu, C. C.; Bastow, K. F.; Brossi, A.; Lee, K.-H. Synthesis of water-soluble colchicine derivatives. Bioorg. Med. Chem. Lett. 2005, 15, 235-238.
15. (b) Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J. Med. Chem. 2005, 48, 6107-6116.
16. (c) Zhang, S.-X.; Feng, J.; Kuo, S.-C.; Brossi, A.; Hamel, E.; Tropsha, A.; Lee, K.-H. Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis. J. Med. Chem. 2000, 43, 167-176.
17. Davis, P. D.; Dougherty, G. J.; Blakey, D. C.; Galbraith, S. M.; Tozer, G. M.; Holder, A. L.; Naylor, M. A.; Nolan, J.; Stratford, M. R. L.; Chaplin, D. J.; Hill, S. A. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 2002, 62, 7247-7253.
18. Joncour, A.; Décor, A.; Liu, J.-M.; Tran Huu Dau, M.-E.; Baudoin, O. Asymmetric synthesis of antimicrotubule biaryl hybrids of allocolchicine and steganacin. Chem. - Eur. J. 2007, 13, 5450-5465.
19. (a) Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem. 2006, 49, 3033-3044.
20. (b) Srivastava, V.; Negi, A. S.; Kumar, J. K.; Gupta, M. M.; Khanuja, P. S. Plant-based anticancer molecules: A chemical and biological profile of some important leads. Bioorg. Med. Chem. 2005, 13, 5892-5908.
21. Brancale, A.; Silvestri, R. Indole, a core nucleus for potent inhibitors of tubulin polymerization. Med. Res. Rev. 2007, 27, 209-238.
22. Fuller, R. W.; Molloy, B. B.; Day, W. A.; Roush, B. W.; Marsh, M. M. Inhibition of phenylethanolamine N-methyltransferase by benzylamines. 1. Structure-activity relationships. J. Med. Chem. 1973, 16, 101-106.
23. Peukert, S.; Brendel, J.; Hemmerle, H.; Kleemann, H.-W. PCT Int. Appl. WO 0248131 A1 20020620, 2002.
24. Sakamoto, T.; Nagano, T.; Kondo, Y.; Yamanaka, H. Palladium-catalyzed coupling reaction of 3-iodoindoles and 3-iodobenzo[b-]thiophene with terminal acetylenes. Chem. Pharm. Bull. 1988, 36, 2248-2252.
25. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
26. 50 for growth inhibition of MCF-7 cells by this compound determined by these authors was 1.2 μM, similar to the value determined in KB cells in our study (Table 1). No indications were given as to the possible mode of action of 4a. See Putey, A.; Joucla, L.; Picot, L.; Besson, T.; Joseph, B. Synthesis of latonduine derivatives via intramolecular Heck reaction. Tetrahedron 2007, 63, 867-879.
27. Kung, A. L.; Zetterberg, A.; Sherwood, A. W.; Schimke, R. T. Cytotoxic effects of cell cycle specific agents: a result of cell cycle perturbation. Cancer Res. 1990, 50, 7307-7314.
28. Chang, M. P.; Bramhall, J.; Graves, S.; Bonavida, B.; Wisnieski, B. J. Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J. Biol. Chem. 1989, 264, 15261-15267.
29. McGahon, A.; Bissonnette, R.; Schmitt, M.; Cotter, K. M.; Green, D. R.; Cotter, T. G. Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994, 83, 1179-1187.
30. McGahon, A. J.; Nishioka, W. K.; Martin, S. J.; Mahboubi, A.; Cotter, T. G.; Green, D. R. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 1995, 270, 22625-22631.
31. Gangemi, R. M.; Tiso, M.; Marchetti, C.; Severi, A. B.; Fabbi, M. Taxol cytotoxicity of human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother. Pharmacol. 1995, 36, 385-392.
32. Dubrez, L.; Goldwasser, F.; Genne, P.; Pommier, Y.; Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995, 9, 1013-1024.
33. Ray, S.; Bullock, G.; Nunez, G.; Tang, C.; Ibrado, A. M.; Huang, Y.; Bhalla, K. Enforced expression of Bcl-xs induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-β-D- arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Diff. 1996, 7, 1617-1623.
34. Gu, Y.-Y.; Zhang, H.-Y.; Zhang, H.-J.; Li, S.-Y.; Ni, J.-H.; Jia, H.-T. 8-Chloro-adenosine inhibits growth at least partly by interfering with actin polymerization in cultured human lung cancer cells. Biochem. Pharmacol. 2006, 72, 541-550.
35. Chen, Y.-L.; Lin, S.-Z.; Chang, J.-Y.; Cheng, Y- L.; Tsai, N.-M.; Chen, S.-P.; Chang, W.-L.; Ham, H.-J. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochem. Pharmacol. 2006, 72, 308-319.
36. Hagedorn, M.; Javerzat, S.; Gilges, D.; Meyre, A.; de Lafarge, B.; Eichmann, A.; Bikfalvi, A. Accessing key steps of human tumor progression in vivo using an avian embryo model. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 1643-1648.
37. Venot, C.; Maratrat, M.; Dureuil, C.; Conseiller, E.; Bracco, L.; Debussche, L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 1998, 17, 4668-4679.
38. Shelanski, M. L.; Gaskin, F.; Cantor, C. R. Microtubule assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci. U.S.A. 1973, 70, 765-768.
39. Hagedorn, M.; Zilberberg, L.; Wilting, J.; Canron, X.; Carrabba, G.; Giussani, C.; Pluderi, M.; Bello, L.; Bikfalvi, A. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res. 2002, 62, 6884-6890.